ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

165
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
05 Jun 2024 19:02Broker

Equity Investment Strategy: Post Lok Sabha Election 2024

On 4th June 2024, three election results were due 1) Loksabha election 2024, 2) State election results of Andra pradesh, and 3) State election...

Logo
234 Views
Share
04 Jun 2024 06:45Broker

Axis Top Picks for the Month of June 2024

The Axis Top Picks Basket delivered an excellent return of 5.4% in the last three months against the 2.5% return posted by Nifty 50, thereby...

Logo
263 Views
Share
bullishCummins India
29 May 2024 12:14

NIFTY200 Momentum30 Index Rebalance Preview: 49% Turnover; US$850m Trade; Election Results Coming

There could be 13 changes for the Nifty200 Momentum 30 Index in June. The potential adds have outpeformed the potential deletes. Results of the...

Logo
387 Views
Share
bullishCipla Ltd
21 May 2024 20:38

Cipla (CIPLA IN): Strong Q4 Performance; Future Growth Drivers Being Added; Promoter Stake Sale

​Cipla reports double-digit revenue and EBITDA growth, and margin expansion in Q4, riding on US, India, and South Africa businesses. For FY25, the...

Logo
356 Views
Share
bullishIndegene
10 May 2024 11:28

Indegene IPO Trading - High Anchor Quality + Strong Demand, Expect a Pop on Debut

Indegene Limited (1864095D IN) raised around US$220m in its India IPO, via selling a mix of primary and secondary shares. In this note, we will...

Logo
457 Views
Share
x